Rice Hall James & Associates’s Eli Lilly LLY Stock Holding History

Rice Hall James & Associates’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Hold	1,615	–	–	0.09%	178
2026 Q1	$1.49M	Sell	1,615 -75	-4%	-$76K	0.08%	184
2025 Q4	$1.82M	Hold	1,690	–	–	0.1%	169
2025 Q3	$1.29M	Hold	1,690	–	–	0.07%	190
2025 Q2	$1.32M	Hold	1,690	–	–	0.07%	188
2025 Q1	$1.4M	Hold	1,690	–	–	0.08%	185
2024 Q4	$1.3M	Hold	1,690	–	–	0.07%	193
2024 Q3	$1.5M	Sell	1,690 -150	-8%	-$135K	0.08%	190
2024 Q2	$1.67M	Hold	1,840	–	–	0.1%	176
2024 Q1	$1.43M	Sell	1,840 -50	-3%	-$35.6K	0.08%	192
2023 Q4	$1.1M	Hold	1,890	–	–	0.06%	213
2023 Q3	$1.02M	Sell	1,890 -50	-3%	-$25.8K	0.06%	204
2023 Q2	$910K	Sell	1,940 -50	-3%	-$21K	0.05%	221
2023 Q1	$683K	Sell	1,990 -150	-7%	-$50.6K	0.04%	239
2022 Q4	$783K	Hold	2,140	–	–	0.04%	237
2022 Q3	$692K	Hold	2,140	–	–	0.04%	240
2022 Q2	$694K	Sell	2,140 -150	-7%	-$45K	0.03%	236
2022 Q1	$656K	Sell	2,290 -100	-4%	-$25.7K	0.03%	247
2021 Q4	$660K	Hold	2,390	–	–	0.02%	250
2021 Q3	$552K	Hold	2,390	–	–	0.02%	255
2021 Q2	$549K	Sell	2,390 -100	-4%	-$20.1K	0.02%	257
2021 Q1	$465K	Hold	2,490	–	–	0.02%	261
2020 Q4	$420K	Hold	2,490	–	–	0.01%	262
2020 Q3	$369K	Hold	2,490	–	–	0.01%	251
2020 Q2	$409K	Hold	2,490	–	–	0.02%	248
2020 Q1	$345K	Hold	2,490	–	–	0.02%	251
2019 Q4	$327K	Hold	2,490	–	–	0.01%	254
2019 Q3	$278K	Hold	2,490	–	–	0.01%	261
2019 Q2	$276K	Hold	2,490	–	–	0.01%	267
2019 Q1	$323K	Hold	2,490	–	–	0.01%	278
2018 Q4	$288K	Hold	2,490	–	–	0.01%	279
2018 Q3	$267K	Hold	2,490	–	–	0.01%	289
2018 Q2	$212K	Buy	+2,490	New	+$205K	0.01%	291
2018 Q1	–	Sell	-2,490	Closed	-$210K	–	300
2017 Q4	$210K	Hold	2,490	–	–	0.01%	294
2017 Q3	$213K	Hold	2,490	–	–	0.01%	283
2017 Q2	$205K	Hold	2,490	–	–	0.01%	285
2017 Q1	$209K	Buy	+2,490	New	+$199K	0.01%	290
2016 Q1	–	Sell	-2,940	Closed	-$248K	–	303
2015 Q4	$248K	Hold	2,940	–	–	0.01%	290
2015 Q3	$246K	Hold	2,940	–	–	0.02%	288
2015 Q2	$245K	Hold	2,940	–	–	0.01%	296
2015 Q1	$214K	Sell	2,940 -310	-10%	-$22.1K	0.01%	305
2014 Q4	$224K	Sell	3,250 -300	-8%	-$20.3K	0.01%	294
2014 Q3	$230K	Hold	3,550	–	–	0.02%	285
2014 Q2	$221K	Sell	3,550 -100	-3%	-$5.97K	0.01%	292
2014 Q1	$215K	Sell	3,650 -400	-10%	-$22.3K	0.02%	292
2013 Q4	$207K	Hold	4,050	–	–	0.01%	292
2013 Q3	$204K	Sell	4,050 -450	-10%	-$23.6K	0.02%	269
2013 Q2	$221K	Buy	+4,500	New	+$245K	0.02%	264

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rice Hall James & Associates's LLY Position: Q2 2026 in Review

Rice Hall James & Associates held its Eli Lilly (LLY) position steady in Q2 2026 at 1,615 shares worth $1.94M. The position accounts for 0.09% of the portfolio, ranked #178.

Rice Hall James & Associates first reported a position in LLY in Q2 2013 and has held it in 48 quarters since. 4,627 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Rice Hall James & Associates held 1,615 shares of Eli Lilly worth $1.94M as of Q2 2026.
Rice Hall James & Associates left its Eli Lilly share count unchanged in Q2 2026.
Eli Lilly made up 0.09% of Rice Hall James & Associates's portfolio in Q2 2026, its #178 holding.
Rice Hall James & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 48 quarters since.
4,627 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.